Chapter title |
Microfluidic-Based Manufacture of siRNA-Lipid Nanoparticles for Therapeutic Applications.
|
---|---|
Chapter number | 6 |
Book title |
Drug Delivery System
|
Published in |
Methods in molecular biology, February 2014
|
DOI | 10.1007/978-1-4939-0363-4_6 |
Pubmed ID | |
Book ISBNs |
978-1-4939-0362-7, 978-1-4939-0363-4
|
Authors |
Walsh C, Ou K, Belliveau NM, Leaver TJ, Wild AW, Huft J, Lin PJ, Chen S, Leung AK, Lee JB, Hansen CL, Taylor RJ, Ramsay EC, Cullis PR, Colin Walsh, Kevin Ou, Nathan M. Belliveau, Tim J. Leaver, Andre W. Wild, Jens Huft, Paulo J. Lin, Sam Chen, Alex K. Leung, Justin B. Lee, Carl L. Hansen, Robert J. Taylor, Euan C. Ramsay, Pieter R. Cullis, Walsh, Colin, Ou, Kevin, Belliveau, Nathan M., Leaver, Tim J., Wild, Andre W., Huft, Jens, Lin, Paulo J., Chen, Sam, Leung, Alex K., Lee, Justin B., Hansen, Carl L., Taylor, Robert J., Ramsay, Euan C., Cullis, Pieter R. |
Abstract |
A simple, efficient, and scalable manufacturing technique is required for developing siRNA-lipid nanoparticles (siRNA-LNP) for therapeutic applications. In this chapter we describe a novel microfluidic-based manufacturing process for the rapid manufacture of siRNA-LNP, together with protocols for characterizing the size, polydispersity, RNA encapsulation efficiency, RNA concentration, and total lipid concentration of the resultant nanoparticles. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 8 | 17% |
Student > Ph. D. Student | 7 | 15% |
Student > Master | 5 | 10% |
Student > Doctoral Student | 4 | 8% |
Student > Bachelor | 3 | 6% |
Other | 3 | 6% |
Unknown | 18 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 15% |
Agricultural and Biological Sciences | 6 | 13% |
Biochemistry, Genetics and Molecular Biology | 5 | 10% |
Chemical Engineering | 1 | 2% |
Immunology and Microbiology | 1 | 2% |
Other | 3 | 6% |
Unknown | 25 | 52% |